US2017119730A1PendingUtilityA1

Combination Therapy for Effecting Weight Loss and Treating Obesity

60
Assignee: VIVUS INCPriority: Jun 14, 1999Filed: Jun 3, 2016Published: May 4, 2017
Est. expiryJun 14, 2019(expired)· nominal 20-yr term from priority
Inventors:Thomas Najarian
A61P 3/04A61K 31/7048A61K 31/35A61K 31/357A61K 31/137A61K 45/06A61K 31/535A61P 11/00A61K 9/0053A61K 2300/00A61K 31/351
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition formulated for oral administration comprising 25 mg to 100 mg of topiramate, formulated for controlled release, and 5 mg to 15 mg of phentermine, formulated for immediate release. 
     
     
         2 . (canceled) 
     
     
         3 . A method of effecting weight loss in a subject in need thereof by administering a pharmaceutical composition formulated for oral administration comprising 25 mg to 100 mg of topiramate, formulated for controlled release, and 5 mg to 15 mg of phentermine, formulated for immediate release. 
     
     
         4 - 23 . (canceled)

Join the waitlist — get patent alerts

Track US2017119730A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.